Impact Of BCR-ABL1 Monitoring Among Patients With BCR-ABL1-Positive B-Acute Lymphoblastic Leukemia
Acute lymphoblastic leukaemia (ALL) with BCR-ABL1 confers a high risk of relapse and a poor prognosis. Access to the tyrosine kinase inhibitor as part of the treatment strategy has changed the risk stratification for ALL patients harbouring this fusion gene. As BCR-ABL1 is routinely quantified for t...
Saved in: